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ABSTRACT: Therapeutic oligonucleotides, such as small interfering RNAs (siRNAs), provide a 
simple and effective tool to modulate expression of any gene. siRNAs harness the RNA interference 
(RNAi) pathway to degrade disease-associated messenger RNAs (mRNAs). The inherent sequence 
specificity and potency of siRNAs makes them ideal drug candidates that are expected to trans-
form drug development and our approach to human health. However, the first wave of clinical 
trials were not immediately successful and temporarily dampened the excitement over this newly 
discovered technology. Most studies did not meet desired efficacy and failed to achieve clinically-
-relevant endpoints. Poor chemical design, lack of enzymatic stability and inadequate delivery 
strategies were found to be the main issues stifling success.
Recent advancements in RNA chemistry, biology, and mechanistic understanding of factors 
that define oligonucleotide pharmacokinetic/pharmacodynamic behavior have resulted in a 
fundamental shift in the clinical landscape of this novel class of therapeutic modalities . As a result, 
there has been a dramatic increase in both the numbers of clinical trials and, more importantly, 
the level of observed clinical efficacy. In 2018, we witnessed a major landmark for the field with the 
first formulation-based RNAi therapeutic, Patisiran (OnpattroTM), being approved by the Food and 
Drug Administration and the European Medicines Agency. Approximately a year later, another 
breakthrough was achieved with the approval of Givosiran (GIVLAARITM), the first siRNA using 
the conjugate-mediated approach for targeted delivery to hepatocytes. Both these approvals 
brought revitalized hope and enthusiasm to the field, and have restored the interest in RNAi, as 
a powerful disease-modifying therapeutic strategy for a variety of genetically-defined disorders.
This review gives an overview of the clinical landscape of synthetic RNAi drugs, contextualizing 
how advances in RNAi chemistry and formulation strategies have helped define the clinical utility 
of this promising class of drugs.
Keywords: RNA interference; siRNA; miRNA; Therapeutic oligonucleotides; Gene knockdown; Drug 
development.
A era dos medicamentos de ARN interferência: o panorama clínico dos 
fármacos para silenciamento génico
RESUMO: Oligonucleotídeos sintéticos, como os small interfering RNAs (siRNAs), providenciam 
uma forma simples e eficiente de modular a expressão de qualquer gene. siRNAs utilizam um 
mecanismo endógeno, chamado ARN interferência, para degradar ARN mensageiros que estejam 
associados a condições patológicas. A capacidade de silenciar genes com elevada especificidade 
e potência faz dos siRNAs fármacos ideais com um elevado potencial para transformar o ramo da 
medicina e a forma como se faz desenvolvimento farmacêutico. Contudo, os primeiros ensaios 
clínicos com esta tecnologia não tiveram sucesso imediato, o que reduziu temporariamente o 
entusiasmo da comunidade científica. A maioria destes estudos iniciais não atingiram a eficácia 
clínica desejada. A introdução prematura de fármacos que não se encontravam devidamente 
estabilizados e a utilização de estratégias de administração inadequadas foram as principais 
causas dos primeiros fracassos.
Avanços recentes na síntese química de oligonucleotídeos, como a melhor compreensão dos 
processos biológicos que definem a farmacocinética/farmacodinâmica destes fármacos, resultou 
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6numa mudança drástica no panorama clínico desta nova modalidade terapêutica. O número de 
ensaios clínicos tem aumentado significativamente ao longo dos últimos anos, em paralelo com 
o aumento da eficácia terapêutica destes medicamentos. Em 2018 foi testemunhado um marco 
importante para o ramo de desenvolvimento destes fármacos, com a aprovação do primeiro 
produto baseado em liposomas, Patisiran (OnpattroTM), pela Food and Drug Administration e 
pela European Medicines Agency. Aproximadamente um ano mais tarde foi aprovado o primeiro 
fármaco que utiliza a estratégia de conjugados que possibilita a internalização específica em 
hepatócitos, Givosiran (GIVLAARITM). A recente aprovação destes dois fármacos trouxe uma espe-
rança renovada ao ramo de ARN interferência, alimentando o interesse nesta estratégia como 
poderosa ferramenta terapêutica para doenças do foro genético. 
Este artigo de revisão pretende providenciar uma perspetiva geral sobre o panorama clínico 
dos fármacos para silenciamento génico, contextualizando o papel dos avanços tecnológicos que 
permitiram a definição desta modalidade como uma nova classe farmacêutica. 
Palavras-chave: ARN interferência; siRNA; miRNA; Oligonucleotídios para terapêutica; Desenvolvi-
mento de novos fármacos.
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Introduction
Gene silencing oligonucleotides hold great promise as 
disease-modifying therapies for genetically-defined disor-
ders by inhibiting the expression of toxic gene products. The 
inherent sequence-specificity of these approaches enables 
gene silencing through messenger RNA (mRNA) degradation, 
providing an attractive therapeutic alternative for molecular 
targets that have been deemed ‘undruggable’ by small mole-
cules. In this context, post-transcriptional gene silencing has 
been achieved using several classes of oligonucleotides, such 
as ribozymes, antisense oligonucleotides (ASOs) and RNA 
interference (RNAi)-based oligonucleotides. Among these, 
RNAi-based oligonucleotides have gained remarkable atten-
tion due to their potency and long-lasting gene knockdown 
effects. Indeed, since the first observation more than 25 years 
ago in petunias1, to the identification of the RNAi pathway 
in the nematode C. elegans2 and translation to mammalian 
systems3, the applications of this young technology have 
grown considerably. RNAi has not only become an invaluable 
research tool to study gene function and dissect complex 
biochemical pathways, but has also emerged as a viable 
therapy, with the first product (Patisiran, OnpattroTM) being 
recently approved by the Food and Drug Administration 
(FDA) and European Medicines Agency (EMA)4.
Although several approaches have been used to hijack the 
RNAi pathway experimentally, synthetic small interfering 
RNAs (siRNAs) have dominated the clinical landscape of RNAi-
-based drugs. Capitalizing on lessons learned from the clinical 
development of ASOs and other oligonucleotides5, synthetic 
RNAi-based drugs exhibited early and rapid progress to the 
clinic, with the first two drug candidates beginning clinical 
trials in 2004. These studies were mainly initiated by small 
biotechnology companies, but the following years were 
characterized by enormous investment from big pharma-
ceutical companies that propelled several other drug candi-
dates to the clinic6. The lack of clinically-relevant efficacy in 
many of the initial trials caused the scientific community to 
re-think rational approaches for tackling challenges such as 
poor stability and acute immunostimulatory effects upon 
administration. In factHowever, recent advancements in RNA 
chemistry, biology, and the mechanistic understanding of 
factors defining oligonucleotide pharmacokinetic (PK)/ phar-
macodynamic (PD) behavior7, have resulted in a fundamental 
shift in clinical efficacy with several candidates likely to join 
Patisiran as approved products in the near future.
This review will provide a basic overview of the endoge-
nous RNAi pathway, and the approaches used to harness 
gene silencing machinery for therapeutic applications. Parti-
cular attention will be paid to aspects of siRNA design and 
delivery. Finally, this review will provide a historical journey 
of the clinical landscape of synthetic RNAi drugs, examining 
how rational design of candidates and delivery strategies 
have shaped 15 years of clinical development.
The RNA interference pathway
The RNAi pathway is used by eukaryotic cells to regulate 
gene expression (Figure 1). It is thought to have evolved from 
viral defense mechanisms8, and starts with a long double-s-
tranded RNA (dsRNA) that is processed into 21-23 nucleoti-
de-long siRNAs by a cytosolic RNase called Dicer9. The cano-
nical siRNA duplex consists of a guide strand and a passenger 
strand that are fully complementary in their central region 
(19-nt) and contain unpaired 2-nt overhangs at the 3’-ends of 
each strand. The guide strand is selected based on its ther-
modynamic instability at the 5’-end, and is loaded into the 
RNA-Induced Silencing Complex (RISC), while the passenger 
strand is cleaved and discarded by Argonaute 2 (Ago2)9. 
Thereafter, RISC actively searches for the mRNA target, binds 
via Watson-Crick base pairing, and silences it by Ago2-me-
diated cleavage. After cleaving the target, RISC is free to 
search the transcriptome again and degrade other comple-
mentary mRNAs.
A class of endogenous non-coding RNAs, termed micro 
RNAs (miRNAs), also use RNAi machinery to modulate various 
cellular pathways9. miRNAs are encoded within the host 
genome as stand-alone individual genes, gene clusters, 
7or introns, and are transcribed by RNA polymerase II9. The 
initial transcript is called primary (Pri)-miRNA and consists 
of a single strand RNA molecule that self-hybridizes forming 
an imperfectly-matched duplex containing terminal hairpin 
loops (Figure 1). Pri-miRNA is processed by Drosha to form a 
20-25 nt-long precursor termed (Pre)-miRNA, which is then 
exported from the nucleus to the cytoplasm by exportin 59. In 
the cytoplasm, Dicer further processes this small RNA duplex 
to remove the stem loop structure, and the final miRNA 
product is loaded into RISC. However, unlike siRNAs, miRNAs 
do not require perfect complementarity to their target to 
exert an effect. miRNA-programmed RISC complexes can 
modulate multiple mRNA targets by binding the 3’- untrans-
lated region (UTR), causing both mRNA relocalization/degra-
dation and ribosomal translational arrest9. miRNA dysregula-
tion may detrimentally affect transcriptome homeostasis and 
result in disease (e.g. cancer, cardiovascular diseases, neuro-
degenerative disease)10. Thus, in addition to their applications 
as therapeutic intervention, miRNAs can serve as biomarkers 
to characterize or diagnose certain disease pathologies.
The RNAi pathway holds great potential for therapeutic 
modulation of gene expression. The multiple turnover acti-
vity of RISC allows for potent and sustained gene silencing 
of virtually any given mRNA target. This particular feature 
spurred great interest in the scientific community that rapidly 
developed strategies to harness this endogenous pathway 
for therapeutic gene silencing. The next section reviews 
these approaches.
Hijacking the RNA interference pathway for therapeutic 
gene silencing
Approaches to artificially hijack RNAi for therapeutic 
purposes can be broadly classified as: (i) Viral based, i.e. deli-
vering an expression vector or virus encoding a short-harpin 
RNA (shRNA) or miRNA; and (ii) Non-viral, i.e. delivering 
synthetic siRNA or miRNA. 
Viral-based RNAi delivery has numerous advantages 
owing to the variety of recombinant viruses that have been 
engineered for research and therapeutics11-12. Depending on 
the application, recombinant viruses are selected based on 
their tropism for a specific cell-type or organ-system, and in 
their capacity to integrate into the host genome. RNAi deli-
very through a virus allows for continuous expression of the 
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Figure 1. The mechanism of RNA interference.
The RNA interference (RNAi) pathway is as an endogenous regulatory pathway that enables modulation of gene expression. The biogenesis of micro
RNAs (miRNAs) (A) and small interfering RNAs (siRNAs) (B) are depicted above.
8shRNA or miRNA over extended periods of time, resulting in 
long-lasting gene silencing effects after a single administra-
tion12. Although vector-induced immunological responses 
were associated with fatalities in the clinic during the early 
2000’s11,13, the safety of this approach has improved consi-
derably thanks to advancements in vector engineering. In 
fact, several gene therapy products for gene substitution 
have been approved in recent years, including Glybera® 
(Alipogene tiparvovec) for lipoprotein lipase deficiency, 
IMLYGIC® (talimogene laherparepvec) for melanoma, and 
Zolgensma (onasemnogene abeparvovec-xioi) for spinal 
muscular atrophy14. However, only a handful of trials have 
been initiated to test the utility of viral-based RNAi for thera-
peutic gene modulation, mostly focusing on ex vivo approa-
ches. An overview of the clinical landscape of viral-based 
RNAi is out of the scope of this paper, but the potential of 
this approach for in vivo therapeutic gene silencing has been 
recently reviewed elsewhere12,15. 
By far, non-viral delivery of synthetic siRNA or miRNA is 
more commonly used to induce therapeutic RNAi in the 
clinic. Oligonucleotides and transfection reagents can be 
synthesized in the lab in a controlled fashion, and can be 
easily scaled-up for production. However, non-viral delivery 
of synthetic RNAi drugs have faced its own set of challenges 
over the years, including: poor stability in serum, rapid renal 
clearance, immunogenicity, off-target effects, limited tissue 
distribution, reduced or non-specific cellular uptake, and 
inadequate subcellular localization7. The next section will 
discuss the design and delivery considerations for enhancing 
the therapeutic utility of synthetic RNAi drugs.
Design and delivery considerations for synthetic RNAi 
drugs
Several algorithms have been developed and are available 
online for the design of potent siRNAs against any given 
mRNA target16-19. These algorithms avoid regions/sequences 
that share complementarity with other transcripts to reduce 
possible off-target effects; but also, avoid regions within the 
target mRNA with complex secondary structures, since these 
are inaccessible to the loaded RISC. Mismatches in the seed 
region (nt 2-7 of the guide strand) are not well tolerated 
and will drastically reduce gene silencing activity; and thus, 
should also be avoided. The remainder of the sequences are 
generally sorted based on established criteria, including: 
specificity, base preference composition, seed complement 
frequency/low seed frequency, and thermodynamic bias (e.g. 
GC content)18-19. Strand bias, achieved by generating duplexes 
with low internal stability at the 3’-end of the passenger 
strand, is particularly important since it determines loading 
of the guide strand into RISC, greatly reducing off-target 
effects18. After sequence design, lead compounds are iden-
tified based on large in vitro screens in relevant cell cultures. 
The top compounds are then selected based on potency 
(EC50) for in vivo evaluations. 
Delivery of nucleic acids in vivo to target tissues of thera-
peutic interest has been a major challenge in the field. siRNAs 
and miRNAs have poor drug-like properties: they are fairly 
large (12-14 kDa) and highly hydrophilic, with a negatively-
-charged phosphate backbone (~40 negative charges)7. 
These unfavorable PK characteristics result in poor tissue 
distribution and cellular internalization, and rapid clearance 
by glomerular filtration after systemic administration20. 
Moreover, unmodified siRNAs are prone to fast enzymatic 
degradation by endo- and exonucleases, which further 
reduces their half-life in both blood and tissue, and negatively 
impacts their efficacy7. Finally, unmodified siRNAs can induce 
unexpected immunoinflammatory responses through toll-
-like receptors (TLR), such as TLR3 and TLR721-22, and activation 
of Retinoic acid-inducible gene (RIG-I) and dsRNA-dependent 
protein kinase (PKR)23-24. Chemically modifying synthetic RNAi 
drugs has been explored as a strategy to abrogate immunos-
timulatory effects and improve stability and tissue accumu-
lation. The next section reviews the most common modifica-
tions employed in current RNAi-based therapeutics.
Chemical modification of synthetic RNAi drugs
Synthetic siRNAs and miRNAs may be modified at several 
sites within their structure, including the phosphate 
backbone, sugar moieties or nitrous bases5,25. Substitu-
ting one of the non-bridging oxygens on the phosphate 
backbone with a sulfur—a phosphorothioate (PS) backbone 
modification—confers substantial resistance to nuclease 
degradation, and facilitates binding to plasma proteins for 
enhanced circulation time in the blood. The most common 2’ 
sugar modifications, 2’fluoro (2’F) and 2’-methoxy (2’-O-me-
thyl), confer nuclease resistance and reduce recognition by 
the imune system25. Larger chemical groups may be used for 
2’-ribose modifications, provided that the steric constraints of 
siRNA loading into Ago2 are properly considered. Synthetic 
phosphorylation of the 5’-end of the guide strand has been 
successfully employed as a rational strategy to facilitate its 
loading into RISC; and stabilization of this moiety using phos-
phate analogs improves metabolic resistance and substan-
tially enhances the duration of effect26. Several other modi-
fications (reviewed elsewhere25), such as base modifications, 
have been tested in the lab, but have not yet progressed to 
the clinic. 
Chemical modifications can be used to enhance stability 
and reduce immunological responses, but additional strate-
gies are required to aid tissue distribution and cellular inter-
nalization. For in vivo applications, two main strategies are 
used: (i) Formulation, which can be employed with or without 
chemical modifications, and (ii) Conjugation, which relies 
heavily on chemical modifications to protect the oligonucleo-
tide from nucleases. The next section discusses the advances 
in formulation- and conjugation-based delivery strategies.
Delivery strategies for RNAi drugs
Formulation
A wide variety of biomaterials have been used in the 
clinic to enhance distribution and promote cellular uptake 
of drugs, including nucleic acids27-28. Examples of such are 
cationic lipids (e.g. D-Lin-MC3-DMA), polymers (e.g. cyclo-
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9dextrin-based polymers and biocollagen), polypetides, and 
exosomes. Generally, these materials interact with nucleic 
acids and self-assemble into nanoparticles that protect 
the cargo from enzymatic degradation. Cationic non-viral 
vectors confer a positive surface charge to the complex 
that facilitates interaction with negatively-charged cellular 
membranes and endocytosis27-28. Nanosystems may be engi-
neered to promote release from the endosomal compart-
ment by including endosomolytic moieties (e.g. melittin-like 
peptides) or fusogenic lipids (e.g. DOPE) that enable imme-
diate release of siRNAs to the cytoplasm27-28. Thus, nanocar-
riers can drastically reduce dose requirements by improving 
the PK and distribution profiles of siRNAs in vivo after intrave-
nous administrations. However, some nanosystems they have 
been associated with toxicities, mostly caused by aggrega-
tion and subsequent deposition in small capillary beds, such 
as alveolar capillaries in the lung. To limit this issue, advanced 
delivery systems include a ‘stealth’ layer, usually consisting 
of a polyethylenoglycol (PEG)-lipid, that masks the positive 
charge and considerably reduces aggregation in vivo27-28. The 
significant advancements in nanoparticle design were funda-
mental for the approval of the first RNAi-based drug.
Conjugation
Direct conjugation of ligands to improve bioavailability 
of RNAi drugs has gained significant traction as an effective 
alternative to formulation, especially since RISC-compatible 
chemical modification patterns have been identified. Ligands 
have been successfully attached to the 5’- and/or 3’-end of 
the sense strand without affecting RISC loading20. In the 
lab, a very diverse list of ligands, including lipids, carbohy-
drates and peptides have been investigated (e.g. cholesterol, 
transferrin, tat peptide, GLP1, folate, vitamin E and N-ace-
tylgalactosamine (GalNAc)20. Lipid bioconjugates, such as 
cholesterol and docosahexanoic acid (DHA), promote broad 
functional delivery to many different tissues, and possess 
distinct distribution profiles. Thus, the choice of conjugated 
modality is determined by the desired target tissue20. The 
distinctive distribution profiles of different conjugates is 
believed to be, at least in part, a result of differential partitio-
ning to serum proteins20,29. On the other hand, ligands, such 
as GalNAc, enable targeted delivery to specific cell-types by 
hijacking receptor systems30. In this case, GalNAc-siRNAs bind 
to the asialoglycoprotein receptor (ASGPR), which is highly 
expressed by hepatocytes, allowing for targeted delivery to 
the liver. Currently, this is the most impactful targeted-deli-
very platform in the clinical setting31. Many other ligands and 
oligonucleotide scaffolds are now being considered in the 
lab, and are expected to enter clinical development in the 
next few years.
The advances in chemical modification, formulation, and 
conjugation have shaped the clinical landscape of synthetic 
RNAi drugs over the last few decades. The next section will 
recount the evolution of RNAi drug candidates that entered 
clinical development, discussing failures, as well as rising 
trends and strategies in the field. 
Historical perspective on the clinical landscape of 
synthetic RNAi drugs
Synthetic RNAi-based compounds made their debut on the 
clinical stage in 2004. Since then, more than 60 drug candi-
dates have been or are currently being evaluated (Figure 2 
and Table 1), with 144 clinical trials (enrolling an estimated 
total of ~30,000 patients) either carried out or in progress 
(Figure 2). Most trials conducted in the early years of this tech-
nology did not progress beyond Phases I and II, which test 
safety, PK/PD, and initial therapeutic efficacy. After significant 
improvements in stability and delivery strategies a steady 
and considerable increase in the number of Phase III trials 
was observed from 2013 (Figure 2a). In August 2018, a major 
landmark in the field was achieved, with the first RNAi drug 
(Patisiran, OnpattroTM) being approved by the FDA4.
The early years: challenges with partially-modified 
siRNAs, and the emergence of formulation
With the safety of RNAi-based drugs being unknown, it 
was critical for initial clinical trials to focus on local adminis-
tration, carefully consider administration routes, and limit 
drug effects to a localized site before testing systemic admi-
nistration. The first clinical trials focused on ocular delivery. 
The eye was a rational first choice for inaugural studies in the 
clinic because it is an immune-privileged organ and intravi-
treal injections can be performed routinely as an out-patient 
procedure. In these trials, minimally-modified siRNAs, Bevasi-
ranib or AGN211745, were used in the eye against the vascular 
endothelial growth factor (VEGF) or VEGF Receptor, respecti-
vely (Figure 2b-f, Table 1). These siRNAs were locally injected 
in the eyes of patients with age-related macular degenera-
tion to block the angiogenic effects of VEGF, reduce macular 
edema, and improve visual acuity32-33. Around the same time, 
other local routes of administration were explored, including 
intranasal (ALN-RSV01), intratumoral (ATN-RNA) and intra-
dermal (TD101), to treat different conditions (Table 1). Among 
the first systemically-injected siRNAs was the unformulated, 
partially-modified Teprasiran, which targeted p53 for the 
treatment of acute kidney injury34. Despite encouraging 
safety and tolerability results in the aforementioned trials, 
most programs were terminated because primary clinical 
outcomes were unlikely to be met, or serious adverse events 
occurred. Unmodified or partially modified siRNAs employed 
in these trials were likely to have been readily degraded in 
vivo upon injection, and were unable to achieve meaningful 
therapeutic effect. Furthermore, the higher doses require-
ments likely caused toxicities, immunostimulatory effects 
elicited through TLRs, PKR and RIG-I24. Together these results 
led to a wave of disappointment in the field.
To overcome some of the difficulties encountered in these 
first trials, the community turned to formulation approa-
ches. A study sponsored by the University of Duisburg-
-Essen (Germany) was the first to use an anionic liposomal 
system to deliver siRNAs against bcr-abl proto-oncogene 
in a patient with Chronic Myeloid Leukemia35. The liposo-
me-formulated drug was administered intravenously and 
SAÚDE & TECNOLOGIA . MAIO | 2019 | #21 | P. 05-17 . ISSN: 1646-9704
10
SAÚDE & TECNOLOGIA . MAIO | 2019 | #21 | P. 05-17 . ISSN: 1646-9704
Figure 2. The evolution of the clinical landscape of synthetic RNAi drugs.
Clinical trial registry databases, including clinicaltrials.gov, EudraCT, ANZCTR, Japan UMIN-CTR, ChiCTR and ICTRP-WHO, were searched for the 
following terms: RNA interference, RNAi, small interfering ribonucleic acid, small interfering RNA, and siRNA. Registries were also searched for 
specific RNAi industries (e.g. Alnylam pharmaceuticals, Arrowhead pharmaceuticals, etc). All searches were performed by June 2019. (a) Bars indicate 
total number of clinical trials (CTs) per year, categorized by Phase. Red line denotes the grand total of CTs per year. (b) Total number of RNAi drug 
candidates (blue) and CTs (purple) per therapeutic area. (c) Bars represent the number of RNAi drug candidates entering clinical development per 
year, categorized by delivery strategy. Purple line symbolizes the cumulative number of drug candidates entering clinic during the 15 years of 
development. (d) Bars represent the number of CTs initiated per year, categorized by delivery strategy. Purple line symbolizes the cumulative number 
of CTs initiated during the 15 years of development. (e) Bars indicate the cumulative number of RNAi drug candidates comparing local vs. systemic 
approaches. Red line denotes the cumulative number of CTs per local vs. systemic strategies. Information was not available for 2 trials, which were 
excluded from the graph. (f) Pie charts represent the number of RNAi drug candidates (left) and number of CTs (right), and respective percentages, 
per route of administration used.
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produced remarkable downregulation of the target without 
any reported adverse events35. The first large Phase I study 
was conducted by Calando Pharmaceuticals with a cyclodex-
trin (CD)-based polymer as a delivery vehicle for unmodified 
siRNAs targeting RRM2 (CALAA-01)36. In the clinic, this was 
the first example of a targeted delivery system for siRNAs 
that was decorated with transferrin ligands, which enabled 
cellular uptake in solid tumors after intravenous injection36. 
First-generation lipid-based nanoparticles were introduced 
in subsequent years mostly for the treatment of various 
types of cancers (e.g. Atu027), but also for the treatment of 
liver diseases (e.g. ALN-TTR01, PRO-040201). In contrast to 
unformulated siRNAs, their formulated counterparts were 
mostly administered systemically. These systems allowed for 
substantial reductions in dose, but unfortunately many were 
associated with significant immunological responses (e.g. 
cytokine storm) against their biomaterial excipient. Thus, the 
progress of drug candidates relying on first-generation deli-
very systems was halted based on safety concerns.
After the discouraging outcomes of initial trials using 
unmodified (or minimally modified, <50% of nucleotides 
modified) siRNAs and first-generation nanoparticles, there 
was a noticeable slowdown in the number of clinical trials 
being initiated during 2010 and 2011 (Figure 2a, 2c, 2d). Big 
pharmaceutical companies, such as Novartis, Pfizer, Merck, 
Medtronic, Roche and Abbott, pulled out their investments 
or shut-down their in-house programs, aggravating the loss 
of confidence in this technology6. Delivery, stability and anti-
-immunostimulatory strategies needed substantial improve-
ment to regain credibility with the investing community and 
the market.
Advances in formulation and biomaterial design renew 
hope in RNAi-based drugs
Significant efforts and resources were invested in bioma-
terial design to accelerate drug leads into clinical programs. 
Alnylam Pharmaceuticals partnered with Arbutus to test 
subsequent 2nd and 3rd generations of stable nucleic acid 
lipid nanoparticles (SNALP), opening their first program 
for familial hypercholesterolemia (ALN-PCS02) and second 
program for transthyretin (TTR)-mediated amyloidosis (Pati-
siran/ALN-TTR02). The most advanced SNALP generation 
employs a novel D-Lin-MC3-DMA cationic lipid which has 
improved delivery to the liver and a better toxicological 
profile than previous lipids27-28. Arrowhead pharmaceuticals 
also initiated multiple programs (ARC-520 and ARC-AAT) 
using licensed technology from Mirus Bio/Roche—Dynamic 
Polyconjugates (DPC)—that improved the PK and activity 
of siRNAs37. At its core, DPCs consist of a polypeptide-based 
formulation containing a targeting ligand, a membrane-lytic 
peptide (melittin-like peptide) and a shielding molecule, 
such as PEG37. A wide variety of other delivery systems have 
been introduced in the clinic, including EnCore LNPs, LODER 
polymer, vitamin A-coupled LNPs, and biocollagen systems. 
By 2013, formulation-based approaches had surpassed unfor-
mulated siRNAs in the number of drug candidates and clinical 
trials (Figure 2c, 2d).
Nanoparticle formulation allowed the first RNAi drug cock-
tails targeting multiple genes to enter the clinical setting: 
ALN-VSP02 (against KSP and VEGF) and later STP705 (against 
TGF-beta and COX-2), both of which were formulated in LNPs. 
At this time, the first synthetic miRNA mimic (MRX34, mir-34 
mimic) also reached the clinic using LNP-technology to treat 
primary liver cancer, followed by tailored VEDVsPayload in 
2013 and TargomiRs (mir-16 mimic) in 2014, both for lung 
cancer. Therapeutic microRNA mimics have the potential to 
modulate the expression of a broad, yet specific, network of 
transcripts, an approach that might be particularly useful in 
diseases such as cancer38. More recently, exosomes isolated 
from mesenchymal cells have been used as a delivery 
vehicle for siRNAs against KRAS G12D for pancreatic cancer 
(NCT03608631), opening another delivery strategy for gene 
silencing drugs.
Formulation approaches became more successful over 
time as new materials and concepts were evaluated. 
However, vector-mediated toxicities still halted progression 
of most of these delivery platforms. For example, ARC-520 
and ARC-AAT programs using the DPC formulation platform 
presented exciting safety and PK data39-40, but were put on 
hold by the FDA after extended toxicology showed death in 
non-human primates at high doses. Indeed, even the most 
advanced SNALP systems are not innocuous, with a percen-
tage of patients developing infusion-related mild-to-mode-
rate inflammatory reactions and peripheral edema. To mini-
mize the risk, patients are regularly pre-treated with dexa-
methasone (corticosteroid), acetaminophen/paracetamol 
(non-steroidal anti-inflammatory), ranitidine or famotidine 
(H2 blocker) and diphenhydramine (H1 blocker)
39,41. Despite 
this requirement, 3rd generation SNALPs have not being asso-
ciated with any major adverse events, and are considered 
safe.
Lingering safety concerns with formulation-based approa-
ches and significant advances in chemical stabilization of 
therapeutic oligonucleotides allowed for the emergence 
of another valid strategy in the clinic: conjugate-mediated 
delivery20.
Emergence of conjugation as the dominant delivery 
paradigm in the clinic
RXi pharmaceuticals pioneered the first clinical trial that 
investigated the therapeutic utility of a conjugated siRNA 
without any formulation using their hydrophobic self-de-
livering asymmetric siRNA scaffold. This consisted of a self-
-delivering hydrophobically-conjugated asymmetric siRNAs 
against connective tissue growth factor (CTGF) injected intra-
dermally for prevention of hypertrophic scarring42. However, 
the most prominent platform currently in the clinic uses a 
trivalent GalNAc ligand for targeted delivery to hepatocytes 
through ASGPR31. The high recycling turnover of ASGPR 
yields high levels of uptake in the liver after a simple subcuta-
neous injection30. Subcutaneous delivery enables convenient 
self-administration by the patient and is less costly for the 
healthcare system. Thus, this approach is preferable to the 
intravenous injections used for formulation-based approa-
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Table 1. Clinical trials conducted using synthetic RNAi drug candidates
T. Area Drug Target Gene Technology Primary Conditions Latest Phase CT Identifier Sponsor Year
Ocular Bevasiranib/Cand5 VEGF Minimally/Partially modified siRNA Age Related Macular Degeneration Phase 3 NCT00557791 OPKO Health, Inc. 2004
AGN211745/sirna-027 VEGFR1 Minimally/Partially modified siRNA Age Related Macular Degeneration Phase 2 NCT00395057 Allergan|Sirna Therapeutics Inc. 2004
Bamosiran/SYL040012 ADRB2 Minimally/Partially modified siRNA Ocular Hypertension|Open Angle Glaucoma Phase 2 NCT02250612 Sylentis, S.A. 2009
Tivanisiran/SYL1001 TRPV1 Minimally/Partially modified siRNA Ocular Pain|Dry Eye Syndrome Phase 3 NCT03108664 Sylentis, S.A. 2011
PF-04523655/REDD14NP RTP801 Minimally/Partially modified siRNA Age-Related Macular Degeneration Phase 2 NCT01445899 Quark Pharmaceuticals|Pfizer 2007
QPI-1007 CASP2 Minimally/Partially modified siRNA Ischemic Optic Neuropathy Phase 2|Phase 3 NCT02341560 Quark Pharmaceuticals 2010
RXI-109-1501 CTGF Hydrophobic siRNA (sd-rxRNA) Retinal Scarring in Age-related macular degeneration (AMD) Phase 1|Phase 2 NCT02599064 RXi Pharmaceuticals, Corp. 2015
Oncology CatS siRNA CatS Minimally/Partially modified siRNA Liver cancer Phase 1 ChiCTR-RCC-08000279 The First Hospital, Guangxi Medical University 2007
CALAA-01 RRM2 Cyclodextrin NP Cancer|Solid Tumor Phase 1 NCT00689065 Calando Pharmaceuticals 2008
ALN-VSP02 KSP and VEGF SNALP MC3 Lipid Solid Tumors Phase 1 NCT01158079 Alnylam Pharmaceuticals 2009
TKM-080301/TKM-PLK1 PLK1 SNALP MC3 Lipid Cancer With Hepatic Metastases Phase 1|Phase 2 NCT02191878 National Cancer Institute 2010
DCR-MYC MYC LNP EnCore Advanced Solid Tumors Phase 1|Phase 2 NCT02314052 Dicerna Pharmaceuticals, Inc. 2014
MRX34 (mir-34 mimic) LNP (Liposomes) Primary Liver Cancer|Melanoma Phase 1|Phase 2 NCT02862145 Mirna Therapeutics, Inc 2013
VEDVsPayload EGFR (or mir15/16 mimic) EnGeneIC Delivery Vehicles Advanced Solid Tumours Expressing EGFR Phase 1|Phase 2 ACTRN12613001249741 EnGeneIC, LTD. 2013
Atu027 PKN3 LNP (Atuplex) Advanced Solid Tumors|Pancreatic cancer Phase 1|Phase 2 NCT01808638 Silence Therapeutics GmbH 2009
Nek2 siRNA NEK2 Biocollagen delivery system Non curative pancreas cancer Phase 1|Phase 2 JPRN-UMIN000016330 Nagoya University Hospital 2013
siG12D LODER KRASG12D LODER polymer Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer Phase 2 NCT01676259 Silenseed Ltd 2011
iExosomes-KrasG12D siRNA KRASG12D iExosomes Pancreatic Ductal Adenocarcinoma|Pancreatic Cancer Phase 1 NCT03608631 M.D. Anderson Cancer Center 2019
TDM-812 (RPN2siRNA/A6K complex) RPN2 A6K Surfactant-like peptide Treatment-resistant breast cancer Phase 1 JPRN-UMIN000016790 National Cancer Center (Japan) 2015
siRNA-EphA2-DOPC EphA2 LNP (DOPC Neutral Liposomes) Advanced Cancers Phase 1 NCT01591356 M.D. Anderson Cancer Center 2015
ATN-RNA Tenascin-C No / Not specified Glioblastoma multiforme Phase 1|Phase 2 Not reported Not reported 2006
BCR-ABL siRNA BCR-ABL Anionic Liposomes Chronic Myeloid Leukemia Phase 1 Not reported University of Duisburg-Essen 2006
TargomiRs/MesomiRs (mir-16 mimic) EnGeneIC Delivery Vehicles Malignant Pleural Mesothelioma|Non-Small Cell Lung Cancer Phase 1 NCT02369198 University of Sydney 2014
NU-0129 BCL2L12 Gold Nanoparticle/Spherical Nucleic Acid Gliosarcoma|Recurrent Glioblastoma Early Phase 1 NCT03020017 Northwestern University|National Cancer Institute (NCI) 2017
Hepat. Gen. ALN-TTR01 TTR SNALP TTR-mediated Amyloidosis Phase 1 NCT01148953 Alnylam Pharmaceuticals 2010
Patisiran/ALN-TTR02 TTR SNALP MC3 Lipid TTR-mediated Amyloidosis Approved NCT03862807 Alnylam Pharmaceuticals 2012
Revusiran/ALN-TTRSC TTR GalNac-siRNA (STC) conjugate TTR-mediated Amyloidosis Phase 3 NCT02319005 Alnylam Pharmaceuticals 2013
Vutrisiran/ALN-TTRSC02 TTR GalNac-siRNA (ESC) conjugate TTR-mediated Amyloidosis Phase 3 NCT03759379 Alnylam Pharmaceuticals 2019
Givosiran/ALN-AS1 ALAS-1 GalNac-siRNA (ESC) conjugate Acute Intermittent Porphyria Approved NCT03338816 Alnylam Pharmaceuticals 2015
ALN-PCS02 PCSK9 SNALP MC3 Lipid Hypercholesterolemia Phase 1 NCT01437059 Alnylam Pharmaceuticals 2011
Inclisiran/ALN-PCSSC PCSK9 GalNac-siRNA (ESC) conjugate Hypercholesterolemia Phase 3 NCT03814187 Alnylam Pharmaceuticals|The Medicines Company 2014
PRO-040201/TKM-ApoB ApoB SNALP MC3 Lipid Hypercholesterolemia Phase 1 NCT00927459 Tekmira Pharmaceuticals Corporation 2009
ARO-ANG3 Angiopoietin-like protein 3 Targeted RNAi Molecule (TRiM)/GalNAc-siRNA Hypercholesterolemia|Hypertriglyceridemia Phase 1 NCT03747224 Arrowhead Pharmaceuticals 2019
ARO-APOC3 ApoC-III Targeted RNAi Molecule (TRiM)/GalNAc-siRNA Hypertriglyceridemia Phase 1 NCT03783377 Arrowhead Pharmaceuticals 2019
Cemdisiran/ALN-CC5 CC5 GalNac-siRNA (ESC) conjugate Complement-mediated diseases, Proteinuria Phase 2 NCT03841448 Alnylam Pharmaceuticals 2015
Fitusiran/ALN-AT3SC Antithrombin GalNac-siRNA (ESC) conjugate Hemophilia A|Hemophilia B Phase 3 NCT03417102 Alnylam Pharmaceuticals 2014
ALN-AAT AAT GalNac-siRNA (ESC) conjugate Alpha-1 Antitrypsin Deficiency Phase 1|Phase 2 NCT02503683 Alnylam Pharmaceuticals 2015
ALN-AAT02 AAT GalNac-siRNA (ESC+) conjugate Alpha-1 Antitrypsin Deficiency Phase 1|Phase 2 NCT03767829 Alnylam Pharmaceuticals 2016
ARC-AAT AAT Dynamic Polyconjugates Alpha-1 Antitrypsin Deficiency Phase 2 NCT02900183 Arrowhead Pharmaceuticals 2015
ARO-AAT AAT Targeted RNAi Molecule (TRiM)/GalNAc-siRNA Alpha-1 Antitrypsin Deficiency Phase 2|Phase 3 NCT03945292 Arrowhead Pharmaceuticals 2018
AMG 890/ARC-LPA ApoA GalNAc-siRNA Cardiovascular disease Phase 1 NCT03626662 Amgen 2018
ALN-AGT01 Angiotensinogen GalNac-siRNA (ESC+) conjugate Hypertension Phase 1 NCT03934307 Alnylam Pharmaceuticals 2019
Lumasiran/ALN-GO1 Hydroxyacid oxidase 1 GalNac-siRNA (ESC) conjugate Primary Hyperoxaluria Phase 3 NCT03905694 Alnylam Pharmaceuticals 2016
DCR-PH1 Hydroxyacid Oxidase 1 LNP EnCore Primary Hyperoxaluria Type 1 Phase 1 NCT02795325 Dicerna Pharmaceuticals, Inc. 2016
DCR-PHXC Lactate dehydrogenase A GalXC Primary Hyperoxaluria Type 1 Phase 2 NCT03847909 Dicerna Pharmaceuticals, Inc. 2017
ND-L02-s0201 SERPINH1, heat shock protein 47 Vitamin A-Coupled LNP Hepatic Fibrosis (METAVIR F3-4) Phase 1 NCT02227459 Nitto Denko Corporation 2013
Hepat. Inf. ALN-HBV/VIR-2218 HBV GalNac-siRNA (ESC+) conjugate Chronic Hepatitis B Phase 1|Phase 2 NCT03672188 Alnylam Pharmaceuticals 2016
ARC-520 HBV Dynamic Polyconjugates Chronic Hepatitis B Phase 2 NCT02738008 Arrowhead Pharmaceuticals 2013
ARC-521 HBV Dynamic Polyconjugates Chronic Hepatitis B Phase 1 NCT02797522 Arrowhead Pharmaceuticals 2016
ARO-520 HBV Targeted RNAi Molecule (TRiM)/GalNAc-siRNA Chronic Hepatitis B Phase 1|Phase 2 NCT03365947 Arrowhead Pharmaceuticals 2018
DCR-HBVS HBV GalXC Chronic Hepatitis B Phase 1 NCT03772249 Dicerna Pharmaceuticals, Inc. 2018
ARB-001467 HBV SNALP MC3 Lipid Chronic Hepatitis B Phase 2 NCT02631096 Arbutus Biopharma Corporation 2015
Pulmonary ExcellairTM Syk Kinase Minimally/Partially modified siRNA Asthma Phase 2 Not reported ZaBeCor 2009
Pulm. Inf. ALN-RSV01 RSV nucleocapsid Minimally/Partially modified siRNA Respiratory Syncytial Virus Infections Phase 2 NCT01065935 Alnylam Pharmaceuticals 2007
Other Inf. TKM-100201 VP24, VP35, Zaire Ebola L-polymerase SNALP MC3 Lipid Ebola Virus Infection Phase 1 NCT01518881 Tekmira Pharmaceuticals Corporation 2012
TKM-100802 VP24, VP35, Zaire Ebola L-polymerase SNALP MC3 Lipid Ebola Virus Infection Phase 1 NCT02041715 Tekmira Pharmaceuticals Corporation 2014
SXL01 AR-V7 No / Not specified Prostate Cancer Phase 1 NCT02866916 SeleXel |Institut Claudius Regaud 2017
Renal Teprasiran/QPI-1002/I5NP p53 Part. mod. siRNA/Stabilized siRNA Acute Kidney Injury/Delayed Graft Function Phase 3 NCT03510897 Quark Pharmaceuticals 2007
Skin TD101 KRT6a (N171K mutation) Unmodified siRNA Pachyonychia Congenita Phase 1 NCT00716014 TransDerm/Pachyonychia Congenita Project 2008
RXI-109 CTGF Hydrophobic siRNA (sd-rxRNA) Hypertrophic Scar Phase 2 NCT02079168 RXi Pharmaceuticals, Corp. 2012
RXI-SCP-1502 CTGF Hydrophobic siRNA (sd-rxRNA) + DPCP, Samcyprone Human papillomavirus Warths Phase 2 NCT02640820 RXi Pharmaceuticals, Corp. 2015
OLX10010-01 CTGF Self-delivering Asymmetric siRNA Hypertrophic Scar Phase 1 NCT03569267 Olix Pharmaceuticals, Inc. 2018
BMT101 CTGF Self-delivering Asymmetric siRNA Hypertrophic Scar Phase 1 NCT03133130 Olix Pharmaceuticals, Inc.(Biomolec. Therap.)|Hugel 2017
STP705 TGF-beta and COX-2 Histidine Lysine Polypeptide Nanoparticle Hypertrophic Scar Phase 1|Phase 2 NCT02956317 Sirnaomics 2017
Notes: AAT, Alpha-1 antitrypsin. ADRB2, Beta 2 Adrenoreceptor. ALAS-1, 5’-Aminolevulinate Synthase 1. Apo, Apolipoprotein. AR-V7, Androgen-receptor splice variant 7. BCR-ABL, BCR-ABL proto-oncogene. CASP2, Caspase-2. Cbl-b, E3 ubiquitin ligase casitas B-lineage lymphoma-b. CC5, Complement Component 5. COX-2, Cyclooxygenase 2. CTGF, 
connective tissue growth factor. DOPC, 1,2-dioleoyl-sn-glycero-3-phosphocholine. EGFR, epidermal growth factor receptor. EphA2, Ephrin Type-A Receptor 2. EUS, Endoscopic Ultrasound. HBV, Hepatitis B virus. KRASG12D, KRAS Proto-Oncogene. KRT6a, Keratin 6a. KSP, Kinesin spindle protein. LODER, Local Drug EluteR. MYC, MYC Proto-Oncogene. 
NEK2, Never in Mitosis Related Kinase 2. PCSK9, Proprotein Convertase Subtilisin/Kexin Type 9. PKN3, Protein Kinase N3. PLK1, polo-kinase 1. RPN2, Ribophorin II. RRM2, M2 Subunit of Ribonucleotide reductase. RSV, Respiratory syncytial virus. Syk, Spleen tyrosine kinase. TGF-beta, transforming growth factor-beta. TRPV1, Transient Receptor Potential 
Vanilloid-1. TTR, Transthyretin. VEGF, Vascular Endothelial Growth Factor. VEGFR, Vascular Endothelial Growth Factor receptor. VP24, viral protein 24. VP35, viral protein 35. 
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ches. Alnylam Pharmaceuticals were the first RNAi company 
to introduce such a concept, resulting in 7 drug candidates 
being evaluated for different liver indications (Table 1). Many 
other industrial competitors, including Dicerna Pharma-
ceuticals and Silence Therapeutics, followed with their own 
proprietary GalNAc conjugate variants.
The GalNAc platform achieved deeper and uniform pene-
tration into the liver, and a better toxicity profile than LNP 
formulations with no prior or co-administration of immunesu-
pression required. This brought a new wave of enthusiasm to 
the field. By 2015, the clinical landscape reached an inflexion 
point from where formulation-based approaches started to 
lose popularity, and conjugate-mediated delivery (within the 
category of unformulated siRNAs) became the dominating 
paradigm (Figure 2c, 2d). Moreover, the popularity of these 
new GalNAc platforms across many companies significantly 
skewed the focus from local delivery approaches to systemic 
delivery strategies, with the liver as main target (Figure 2e, 2f).
RNAi was once again blossoming with a new and revitalized 
approach that enabled modulation of virtually any gene in 
the liver. However, during the Revusiran Phase 3 trial (ENDEA-
VOUR) in late 2016, an imbalance of mortality between the 
treatment arm (n=18 out of 140) versus placebo (n=2 out of 
66) was reported, and re-ignited concerns about the future 
of RNAi43. Revusiran consisted of a GalNAc-conjugated siRNA 
targeting TTR, essentially an alternative to Patisiran30. In 
contrast to minimally-modified Patisiran, Revusiran used first 
generation chemistry (Standard Template Chemistry, STC) of 
fully modified siRNAs, with a high percentage of 2’-Fluoro 
(~50%) modifications and a limited number of PS substitu-
tions. Although investigations failed to clearly identify the 
cause of the associated toxicities, Alnylam decided to discon-
tinue further development of this candidate.
Revusiran required substantially higher doses (annualized 
dose ~28 g) and more frequent dosing, than other GalNAc 
conjugate programs that used enhanced stabilization 
chemistries (ESC) (e.g. Inclisiran yearly exposure of ~0.6-1.2 
g, dosing every 3-6 months)44-45. ESCs and advanced ESCs 
(ESC+) contain a lower fraction of 2’-fluoro modifications and 
higher amount of 2’-O-Methyl and terminal PS modifications. 
The higher stability and potency of these compounds enable 
up to 6-12 months of gene silencing in the liver after a single 
administration, and thus have been the focus of most drug 
development programs at Alnylam.
The approval of the first RNAi drug
Despite conjugate-mediated approaches dominating the 
clinic landscape, the first approved RNAi drug was Patisiran, 
a LNP-formulated minimally-modified siRNA. Patisiran was 
approved in August 2018 for the treatment of the polyneu-
ropathy of hereditary TTR-mediated amyloidosis41. A wide 
variety of mutations associated with the TTR gene (e.g. V30M 
and V122I0) can destabilize the tretrameric protein, causing 
misfolding and aggregation of the monomers into amyloid 
fibrils46. TTR is produced in the liver, but is released into 
the bloodstream and amyloid fibrils may deposit in several 
organ-systems, including the heart and nervous system46. 
Consequently, patients develop heart-related pathology, 
including hypotension and arrhytmia, and sensorimotor and 
autonomic disturbances that deteriorate movement and 
other daily activities46. 
Patisiran silences the expression of both wild-type and 
mutant forms of TTR in the liver by targeting conserved 
regions at the 3’-UTR of the TTR mRNA. Multi-dose Phase 2 
trials showed dose-dependent reductions of TTR levels in 
serum after intravenous administration of Patisiran47. Two 
consecutive doses of Patisiran (0.3 mg/kg, every 3 weeks) 
reduced TTR levels in serum by 80% (NCT01617967)47. The 
subsequent Phase 3 APOLLO trial showed a significant 
improvement in quality of life, nutrition status, walking, and 
other daily activities, meeting both primary and secondary 
endpoints of the trial41. Patisiran was also found to be well-
-tolerated during the time course of the trials, with only mild-
-to-moderate infusion-related reactions being reported41,47. 
Together, these trials demonstrated that gene silencing is a 
valid approach to halt or reverse TTR-mediated pathology.
Other drug types have been approved for hTTR amyloi-
dosis, including the small molecule drug, Tafamidis, which 
stabilizes TTR46. However, these do not directly target the 
root cause of the disease. Oligonucleotide-based products 
for hTTR amyloidosis have also entered the market (Inotersen, 
TEGSEDI™). Inotersen consists of an ASO that targets the 
TTR mRNA for degradation through a RNase H-mediated 
mechanism48. Clinical trials showed robust silencing and 
clinical improvements48, but substantially higher doses were 
required for therapeutic effect (284 mg/weekly) compared to 
Patisiran (~21-30 mg/3 weeks). Thus, the potency and long-
-lasting efficacy of synthetic siRNAs make RNAi-based thera-
peutics an extremely attractive approach for gene silencing.
Approval of the first conjugated RNAi drug
Late in November 2019, FDA approved the first GalNAc-
-conjugated siRNA, the second synthetic RNAi drug. Givo-
siran (GIVLAARITM) received approval for acute intermittent 
porphyria, a disorder that causes acute neurovisceral attacks 
and takes root in an enzymatic deficiency in heme produc-
tion49-50. Accumulation of delta-aminolevulinic acid (ALA) 
and porphobilinogen leads to acute neurotoxicity, and by 
targeting delta-ALA synthase 1 (ALAS1), Givosiran silences 
the expression of these toxic products and reduces disease 
burden49-50. The Phase 3 ENVISION trial (NCT03338816) 
showed that a subcutaneous monthly administration of 2.5 
mg/kg of Givosiran enabled reduction of urinary levels of 
ALA, but also significantly reduced the rates of porphyria 
attacks requiring hospitalization over a period of 6 months 
(70% fewer attacks than the placebo group)50.
The approval of this first GalNAc-conjugated siRNA esta-
blished a major milestone for targeted delivery approaches 
in the field. The 10x lower doses to achieve therapeutic 
efficacy, the long-lasting silencing effects and the ease of 
subcutaneous administrations made the GalNAc platform a 
remarkable advance for the treatment of liver diseases. In fact, 
the potential of this platform and the recent approval of Givo-
siran prompted the 9.7 billion dollar acquisition of The Medi-
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cines Company by Novartis in an effort to be able to commer-
cialize Inclisiran upon FDA approval. Inclisiran is a GalNAc-
-siRNA targeting proprotein convertase subtilisin/kexin type 
9 (PCSK9) as a strategy to reduce low-density lipoprotein 
cholesterol (LDL-C) levels in the blood stream44-45. Inclisiran 
enables at least 3-6 months of silencing of the PCSK9 target 
and a significant reduction in LDL-C44-45. Although Inclisiran 
was initially being developed for patients with familial hyper-
cholesterolemia, the long duration of effect (up to 6 months) 
encouraged investigators to broaden the scope of indications 
to include Atherosclerotic cardiovascular disease (ASCVD). 
It is believed that, if approved, Inclisiran may become the 
first “RNAi blockbuster” drug that will enable treatment of 
millions of patients around the globe.
The future of RNAi medicines
In the near future, several other RNAi drug candidates are 
expected to receive FDA approval for liver diseases. Most 
of these consist of GalNAc-conjugated fully modified siRNA 
scaffolds, such as Inclisiran, and Lumasiran, all of which are 
currently in Phase 3 trials. Importantly, the clinical success of 
the GalNAc platform has inspired the field to explore other 
conjugated modalities for extra-hepatic delivery. Conjuga-
tion of chemically diverse lipids, carbohydrates, aptamers, 
and antibodies has been shown to drive tissue distribution 
beyond the liver after systemic administration29. Expan-
ding the chemical diversity of siRNAs has also brought frui-
tful results after local administration. In the central nervous 
system, fine-tuning hydrophobicity and construct size has 
been shown to be pivotal for distribution and retention20. As 
seen for liver diseases, once a delivery ligand with suitable 
uptake in a target cell/tissue has been identified, changing 
the target sequence will allow for modulation of any given 
gene target in that tissue. This opens the possibility of develo-
ping disease-modifying treatments for a wide-range of debi-
litating and progressive diseases, provided that the genetic 
target (or targets) has been identified. 
Most applications in the clinic are currently limited to rare 
disorders with a single causative gene. In the future, it is likely 
that treatment of more common and complex diseases will 
be considered. The long-lasting effects (6-12 months) of 
RNAi-based drugs makes them an attractive approach for 
this purpose, and places RNAi medicines on par with other 
therapeutics, such as vaccines, that only require yearly (or 
multi-year) dosing to maintain clinical efficacy. 
Conclusion
Many expect RNAi to become “the monoclonal antibody 
of the 2020s”. Unlike small molecules, which are generally 
restricted to a selected range of protein targets, RNAi directly 
inhibits the protein precursors (mRNA), allowing modulation 
of any disease target. Although the first drug approved by 
regulators consisted of a LNP-formulated siRNA, conjuga-
te-mediated delivery has become the dominant strategy in 
the clinic for liver diseases. This was made possible through 
critical developments in RNA chemistry, that enhanced stabi-
lity and reduced immune responses, accompanied by creative 
new approaches that improved delivery. In the future, disco-
very of new delivery platforms that enable meaningful distri-
bution, accumulation, and durable gene silencing in tissues 
beyond the liver has the potential to accelerate the impact 
of this technology exponentially. Patisiran, the first success in 
the clinic, opened a new chapter for this technology that will 
enable positive change in the lives of many patients, and in 
human medicine, by treating currently incurable disorders.
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